• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Bilateral, central serous chorioretinopathy under BRAF(B-rapidly accelerated fibrosarcoma)-/MEK (mitogen-activated protein kinase kinase)-inhibitor therapy in metastatic cutaneous melanoma.].

作者信息

Rastoaca C, Berger T, Seitz B, Abdin A D

机构信息

Klinik für Augenheilkunde, Universitätsklinikum Essen, Essen, Deutschland.

Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland.

出版信息

Ophthalmologie. 2025 Jan;122(1):52-57. doi: 10.1007/s00347-024-02140-3. Epub 2024 Dec 6.

DOI:10.1007/s00347-024-02140-3
PMID:39643749
Abstract
摘要

相似文献

1
[Bilateral, central serous chorioretinopathy under BRAF(B-rapidly accelerated fibrosarcoma)-/MEK (mitogen-activated protein kinase kinase)-inhibitor therapy in metastatic cutaneous melanoma.].[BRAF（B-快速进展性纤维肉瘤）/MEK（丝裂原活化蛋白激酶激酶）抑制剂治疗转移性皮肤黑色素瘤期间的双侧中心性浆液性脉络膜视网膜病变。]
Ophthalmologie. 2025 Jan;122(1):52-57. doi: 10.1007/s00347-024-02140-3. Epub 2024 Dec 6.
2
[Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].[MEK抑制剂和BRAF抑制剂靶向治疗转移性皮肤黑色素瘤的眼部毒性]
J Fr Ophtalmol. 2022 Jun;45(6):612-618. doi: 10.1016/j.jfo.2021.08.005. Epub 2022 Apr 29.
3
Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma.因MEK抑制用于转移性皮肤黑色素瘤导致的双侧多灶性中心性浆液性脉络膜视网膜病变样病变
Case Rep Ophthalmol Med. 2013;2013:673796. doi: 10.1155/2013/673796. Epub 2013 Mar 11.
4
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.快速加速纤维肉瘤 B 型和/或有丝分裂原激活的细胞外信号调节激酶抑制剂的心血管安全性：一项结合荟萃分析和药物警戒不适当比例分析的混合方法。
Arch Cardiovasc Dis. 2020 Jun-Jul;113(6-7):420-432. doi: 10.1016/j.acvd.2020.03.014. Epub 2020 May 1.
5
Mitogen-activated protein kinase inhibitor-associated retinopathy (MEKAR). A clinical case.丝裂原活化蛋白激酶抑制剂相关性视网膜病变（MEKAR）。一个临床病例。
Arch Soc Esp Oftalmol (Engl Ed). 2022 May;97(5):286-289. doi: 10.1016/j.oftale.2022.02.006. Epub 2022 Feb 26.
6
[Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].[转移性皮肤黑色素瘤治疗期间浆液性视网膜病变的发生]
Ophthalmologe. 2016 Oct;113(10):861-863. doi: 10.1007/s00347-016-0226-8.
7
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.黑色素瘤中的丝裂原活化蛋白激酶途径 I - BRAF 抑制的激活和原发性耐药机制。
Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3.
8
Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy.BRAF和MEK抑制剂治疗期间快速变化的浆液性脱离
Cureus. 2021 Dec 17;13(12):e20491. doi: 10.7759/cureus.20491. eCollection 2021 Dec.
9
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: State-of-the-Art Review.BRAF和MEK抑制剂的心血管毒性：机制与临床概述——最新综述
JACC CardioOncol. 2022 Mar 15;4(1):1-18. doi: 10.1016/j.jaccao.2022.01.096. eCollection 2022 Mar.
10
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.与丝裂原活化蛋白激酶激酶抑制（Binimetinib）相关的浆液性视网膜病变，用于转移性皮肤和葡萄膜黑色素瘤。
Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26.

本文引用的文献

1
A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma.一例与用于转移性皮肤黑色素瘤的BRAF/MEK抑制剂使用相关的双侧多灶性脉络膜炎病例。
Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):2005-2009. doi: 10.1080/09273948.2021.1928714. Epub 2021 May 19.
2
[Uniform classification of the pachychoroid spectrum disorders].[脉络膜增厚谱系疾病的统一分类]
Ophthalmologe. 2021 Aug;118(8):865-878. doi: 10.1007/s00347-021-01379-4. Epub 2021 Apr 26.
3
[Central serous chorioretinopathy].[中心性浆液性脉络膜视网膜病变]
Ophthalmologe. 2021 Sep;118(9):967-980. doi: 10.1007/s00347-021-01376-7. Epub 2021 Apr 16.
4
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.达拉非尼联合曲美替尼治疗转移性黑色素瘤的 5 年结果。
N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
5
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.恩考芬尼加比美替尼与维莫非尼或恩考芬尼用于治疗 BRAF 突变型黑色素瘤患者（COLUMBUS）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.
6
HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.HLA-DRB1*04:05 在两例接受纳武利尤单抗序贯治疗的晚期黑色素瘤患者中出现的与 Vogt-Koyanagi-Harada 病样葡萄膜炎。
J Dermatol. 2018 Jun;45(6):735-737. doi: 10.1111/1346-8138.14273. Epub 2018 Feb 27.
7
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.系统性BRAF/MEK抑制剂作为转移性结膜黑色素瘤的一种潜在治疗选择
Ocul Oncol Pathol. 2017 Jul;3(2):133-141. doi: 10.1159/000452473. Epub 2016 Dec 8.
8
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.转移性黑色素瘤：治疗进展与未来挑战的洞察。
Med Res Rev. 2017 Jan;37(1):98-148. doi: 10.1002/med.21404. Epub 2016 Aug 29.
9
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.与MEK抑制剂用于治疗系统性癌症相关的视网膜下液
JAMA Ophthalmol. 2016 Aug 1;134(8):855-62. doi: 10.1001/jamaophthalmol.2016.0090.
10
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.在使用达拉非尼和曲美替尼治疗黑色素瘤期间发生的严重双侧全葡萄膜炎。
J Ophthalmic Inflamm Infect. 2015 Jun 9;5:17. doi: 10.1186/s12348-015-0049-9. eCollection 2015.